Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H26N4O23P4 |
Molecular Weight | 790.3071 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N3C=CC(=O)NC3=O)N4C=CC(=O)NC4=O
InChI
InChIKey=NMLMACJWHPHKGR-NCOIDOBVSA-N
InChI=1S/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/18600475Curator's Comment: Description was created based on several sources, including http://www.santeninc.com/newsroom/press-releases/10_04_DIQUAS.pdf | http://www.santen.com/en/therapeutic-areas/asia/dryeye/diquas/
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600475
Curator's Comment: Description was created based on several sources, including http://www.santeninc.com/newsroom/press-releases/10_04_DIQUAS.pdf | http://www.santen.com/en/therapeutic-areas/asia/dryeye/diquas/
Diquafosol, a dinucleotide Up4U, is an agonist for purinergic P2Y2 receptor. Diquafosol stimulated water and mucin secretion by acting on P2Y2 receptors on the conjunctival epithelial and goblet cell membrane and elevating intracellular calcium ion concentrations. The Japanese Ministry of Health, Labour and Welfare granted approval for DIQUAS Ophthalmic Solution 3% (diquafosol tetrasodium) for the treatment of dry eye.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4398 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18600475 |
0.1 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DIQUAS Approved UseDIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium) should be used in patients diagnosed with dry eye, associated with keratoconjunctival epithelium disorders that accompany lacrimal fluid abnormality. Launch Date2010 |
PubMed
Title | Date | PubMed |
---|---|---|
Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. | 2001 Apr |
|
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. | 2001 Aug |
|
Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998. | 2003 |
|
Diquafosol tetrasodium. Inspire/Allergan/Santen. | 2003 Nov |
|
Molecule of the month. Diquafosol tetrasodium. | 2003 Oct |
|
Diquafosol tetrasodium: a novel dry eye therapy. | 2004 Jan |
|
Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. | 2004 Mar-Apr |
|
Recent advances in the management of ocular complications of Sjögren's syndrome. | 2005 Jul |
|
P2 receptors activated by uracil nucleotides--an update. | 2006 |
|
New approaches in Sjögren's syndrome therapy. | 2007 Mar |
|
[A molecular marker for dry eye]. | 2007 Mar |
|
Topical application of nucleotides increase lysozyme levels in tears. | 2008 Jun |
|
Preliminary effects of oral uridine on the ocular surface in dry eye patients. | 2009 Aug |
|
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor. | 2011 Jun 23 |
Sample Use Guides
DIQUAS Ophthalmic Solution 3% (generic name: diquafosol tetrasodium). Usually, instill 1 drop a time 6 times daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28280412/
3% diquafosol tetrasodium had a significant, time-dependent, inhibitory effect on human corneal epithelial cells (HCEC) proliferation and cytotoxicity. HCECs treated with diquafosol detached more from the bottoms of dishes and damaged cells showed degenerative changes, such as, reduced numbers of microvilli, vacuole formation, and chromatin of the nuclear remnant condensed along the nuclear periphery.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78283
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40208689
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
C403315
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
59985-21-6
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
SUB87041
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL221326
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
7828VC80FJ
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
4900
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
100000139278
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
148197
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
m4661
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
8326
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
C65436
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
27791
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY | |||
|
DIQUAFOSOL
Created by
admin on Sat Dec 16 15:59:22 GMT 2023 , Edited by admin on Sat Dec 16 15:59:22 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)